Fertility Drug and Surgery Market Research Report – Global Forecast till 2027

Fertility Drug and Surgery Market Research Report, by Underlying Cause (Male and Female), Drugs (Clomiphene Citrate, Letrozole), Procedures (Hysteroscopy, Laparoscopy, Robotic Laparoscopy), and End User (Fertility Clinics) — Global Forecast till 2027

ID: MRFR/HC/6119-HCR | February 2021 | Region: Global | 90 pages

Fertility Drug and Surgery Market Scenario


The fertility drug and surgery market is expected to register a CAGR of 9.8% during the forecast period of 2018 to 2023.


Infertility is a reproductive problem in which the patient could not conceive the baby. Infertility may cause due to the problem in the reproductive system of either partner. There are various treatment & diagnosis methods to cure this problem for both male and female patient.  There are various symptoms faced by infertile men and woman. In a woman, it could be irregular menstrual periods, hormone fluctuation, and in men, it can be semen abnormalities, pelvic infections or sexually transmitted diseases and others.


 The key factors responsible for driving the market growth are an increase in infertility rates, increasing obesity, delayed pregnancies in women, increase in gamete donations, increase in disposable income, also rising healthcare expenditure worldwide is promoting the market growth.


The NIH...Turning Discovery into Health 2018 publication reported that around 11% of women and 9% of men of reproductive age in the US had experienced fertility problems. The increasing cases of infertility due to a sedentary lifestyle and other factors may boost the demand for fertility treatment and drive the market growth. However, the factors such as high cost of treatment, complications related to treatments and low awareness among the population may boost the market growth during the forecast period.


Major Key Players


Some of the key players are Eli Lilly, Baxter Healthcare Corporation, Ferring Pharmaceuticals, Inc., Merck & Co. Pharmaceutical Company, Noven Pharmaceuticalorganon, Inc., Janssen Pharmaceuticals Inc., Personal Products Company, Pfizer, Inc., Procter & Gamble Pharmaceuticals, Emd Serono, Inc., and others.


Intended Audience



  • Fertility Clinics

  • Government and private laboratories

  • Research and Development (R&D) companies

  • Medical research laboratories

  • Market research and consulting service providers


Market Segmentation


The fertility drug and surgery market is segmented on the basis of underlying cause, drug, procedures, end user, and region.


On the basis of the underlying cause, the fertility drug and surgery market is segmented into male and female. By drug, the fertility drug and surgery market is categorized into clomiphene citrate, letrozole, Serophene, hormone treatment, gonadotrophins


aromatase inhibitors, estrogen receptor modulators, dopamine agonists, metformin hydrochloride and others. On the basis of procedures, the fertility drug and surgery market is segmented into hysteroscopy, laparoscopy and robotic laparoscopy, laparotomy/open surgery, egg retrieval, varicocelectomy, vasectomy reversal (vasovasostomy or vasoepididymostomy), sperm retrieval (epididymal aspiration). By end-user, the fertility drug and surgery market is categorized into fertility clinics, hospitals, clinical research institutes, and others.


Regional Market Summary


The Americas dominates the market for fertility drug and surgery owing growing number of infertile couples, delayed pregnancies in the female, growing obesity and increase in disposable income. Also, the adoption of a sedentary lifestyle leads to cause infertility problem among a large number of populations. According to the World Health Organization (WHO), in 2016, 39% of adults aged 18 years and above, i.e., approximately 39% of men and 40% of women were overweight. Additionally, as per the data mentioned by the Heart Foundation, during 2014 to 2015, approximately 28% of all Australian males aged 18 and over were obese, and about 27% of all Australian females aged 18 and over were obese. The increasing obesity among the population may boost market growth in this region.


In 2017, it was estimated that Europe stood second in the fertility drug and surgery market.


It is reported that the rising prevalence of sexually transmitted disease contributes to increasing infertility cases. According to the World Health Organization every year more than 340 million new cases of protozoal infections and sexually transmitted bacterial (STD) across the world. Thus, the increasing reported cases for STD drives the market growth within the region.


Asia-Pacific was the fastest growing region for the fertility drug and surgery market in 2017. Factors such as increasing awareness for women health, growing healthcare industries and development of various treatment methods for infertility drives the market in this region.


On the other hand, the Middle East and Africa holds the least share in the fertility drug and surgery market. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.


Global Fertility Drug and Surgery Market Share (%), by Region, 2017


Drug and Surgery Market


Sources: United Census Bureau, Indian Brand Equity Foundation, International Journal of Women's Health, Annual Reports, Press Release, White Paper, And Company Presentation


Research Methodology


Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.



  • Primary Research


Extensive primary research was conducted to gain a deeper insight into the market and industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.



  • Secondary Research


Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, an international organization of chemical manufacturers, some paid databases, and many others.


Market Segmentation


Fertility Drug and Surgery Market, by Underlying cause



  • Male

  • Female


Fertility Drug and Surgery Market, by Drug



  • Clomiphene Citrate

  • Letrozole

  • Serophene

  • Hormone Treatment

  • Gonadotrophins

  • Aromatase Inhibitors

  • Estrogen Receptor Modulators

  • Dopamine Agonists

  • Metformin Hydrochloride

  • Others


Fertility Drug and Surgery Market, by Procedures



  • Hysteroscopy

  • Laparoscopy and Robotic Laparoscopy

  • Laparotomy/Open Surgery

  • Egg Retrieval

  • Varicocelectomy

  • Vasectomy Reversal

  • Sperm Retrieval


Fertility Drug and Surgery Market, by End-User



  • Fertility Clinics

  • Hospitals

  • Clinical Research Institutes

  • Others



Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

Chapter 6. Global Fertility Drug and Surgery Market, by Underlying Cause

6.1 Overview

6.2 Male

6.3 Female

Chapter 7. Global Fertility Drug and Surgery Market, by Drugs

7.1 Overview

7.2 Clomiphene Citrate

7.3 Letrozole

7.4 Serophene

7.5 Hormone Treatment

7.6 Gonadotrophins

7.7 Aromatase Inhibitors

7.8 Estrogen Receptor Modulators

7.9 Dopamine Agonists

7.10 Metformin Hydrochloride

7.11 Others

Chapter 8. Global Fertility Drug and Surgery Market, by Procedures

8.1 Overview

8.2 Hysteroscopy

8.3 Laparoscopy and Robotic Laparoscopy

8.4 Laparotomy/Open Surgery

8.5 Egg Retrieval

8.6 Varicocelectomy

8.7 Vasectomy Reversal

8.8 Sperm Retrieval

Chapter 9. Global Fertility Drug and Surgery Market, by End Users

9.1 Overview

9.2 Fertility Clinics

9.3 Hospitals

9.4 Clinical Research Institutes

9.5 Others

Chapter 10. Global Fertility Drug and Surgery Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

Chapter 12. Company Profiles

12.1 Eli Lilly

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Baxter Healthcare Corporation

12.3 Ferring Pharmaceuticals, Inc.

12.4 Merck & Co. Pharmaceutical Company

12.5 Noven Pharmaceuticalorganon, Inc.

12.6 Janssen Pharmaceuticals Inc.

12.7 Personal Products Company

12.8 Pfizer, Inc.

12.9 Procter & Gamble Pharmaceuticals

12.10 Emd Serono, Inc.

12.11 Others

Chapter 13 Appendix


LIST OF TABLES

TABLE 1 GLOBAL FERTILITY DRUG AND SURGERY MARKET SYNOPSIS, 2020–2027

TABLE 2 GLOBAL FERTILITY DRUG AND SURGERY MARKET ESTIMATES AND FORECAST, 2020–2027 (USD MILLION)

TABLE 3 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 4 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 5 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 6 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 7 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027(USD MILLION)

TABLE 8 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 9 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 10 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 11 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 12 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 13 US: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 14 US: FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 15 US: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 16 US: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 17 US: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 18 CANADA: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 19 CANADA: FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 20 CANADA: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 21 CANADA: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 22 CANADA: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 23 SOUTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 24 SOUTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 25 SOUTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 26 SOUTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 27 SOUTH AMERICA: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 28 EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 29 EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 30 EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 31 EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 32 EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 33 WESTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 34 WESTERN EUROPE FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 35 WESTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 36 WESTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 37 WESTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 38 EASTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 39 EASTERN EUROPE FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 40 EASTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 41 EASTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 42 EASTERN EUROPE: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 43 ASIA-PACIFIC: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 44 ASIA-PACIFIC FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 45 ASIA-PACIFIC: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 46 ASIA-PACIFIC: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 47 ASIA-PACIFIC: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA: FERTILITY DRUG AND SURGERY MARKET, BY UNDERLYING CAUSE, 2020–2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020–2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA: FERTILITY DRUG AND SURGERY MARKET, BY PROCEDURES, 2020–2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA: FERTILITY DRUG AND SURGERY MARKET, BY END USERS, 2020–2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA: FERTILITY DRUG AND SURGERY MARKET, BY REGION, 2020–2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 SEGMENTATION FOR GLOBAL FERTILITY DRUG AND SURGERY MARKET

FIGURE 3 MARKET DYNAMICS FOR GLOBAL FERTILITY DRUG AND SURGERY MARKET

FIGURE 4 GLOBAL FERTILITY DRUG AND SURGERY MARKET SHARE, BY UNDERLYING CAUSE, 2020 (%)

FIGURE 5 GLOBAL FERTILITY DRUG AND SURGERY MARKET, BY DRUGS, 2020 (%)

FIGURE 6 GLOBAL FERTILITY DRUG AND SURGERY MARKET SHARE, BY PROCEDURES, 2020 (%)

FIGURE 7 GLOBAL FERTILITY DRUG AND SURGERY MARKET SHARE, BY END USERS, 2020 (%)

FIGURE 8 GLOBAL FERTILITY DRUG AND SURGERY MARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: FERTILITY DRUG AND SURGERY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: FERTILITY DRUG AND SURGERY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: FERTILITY DRUG AND SURGERY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: FERTILITY DRUG AND SURGERY MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL FERTILITY DRUG AND SURGERY MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 NOVARTIS AG: KEY FINANCIALS

FIGURE 15 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 16 NOVARTIS AG: GEOGRAPHICAL REVENUE

FIGURE 17 BAXTER HEALTHCARE CORPORATION: KEY FINANCIALS

FIGURE 18 BAXTER HEALTHCARE CORPORATION: SEGMENTAL REVENUE

FIGURE 19 BAXTER HEALTHCARE CORPORATION: GEOGRAPHICAL REVENUE

FIGURE 20 FERRING PHARMACEUTICALS, INC.: KEY FINANCIALS

FIGURE 21 FERRING PHARMACEUTICALS, INC.: SEGMENTAL REVENUE

FIGURE 22 FERRING PHARMACEUTICALS, INC.: GEOGRAPHICAL REVENUE

FIGURE 23 MERCK & CO. PHARMACEUTICAL COMPANY: KEY FINANCIALS

FIGURE 24 MERCK & CO. PHARMACEUTICAL COMPANY: SEGMENTAL REVENUE

FIGURE 25 MERCK & CO. PHARMACEUTICAL COMPANY: GEOGRAPHICAL REVENUE

FIGURE 26 NOVEN PHARMACEUTICALORGANON, INC.: KEY FINANCIALS

FIGURE 27 NOVEN PHARMACEUTICALORGANON, INC.: SEGMENTAL REVENUE

FIGURE 28 NOVEN PHARMACEUTICALORGANON, INC.: GEOGRAPHICAL REVENUE

FIGURE 29 JANSSEN PHARMACEUTICALS INC.: KEY FINANCIALS

FIGURE 30 JANSSEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE

FIGURE 31 JANSSEN PHARMACEUTICALS INC.: GEOGRAPHICAL REVENUE

FIGURE 32 PERSONAL PRODUCTS COMPANY: KEY FINANCIALS

FIGURE 33 PERSONAL PRODUCTS COMPANY: SEGMENTAL REVENUE

FIGURE 34 PERSONAL PRODUCTS COMPANY: GEOGRAPHICAL REVENUE

FIGURE 35 PFIZER, INC.: KEY FINANCIALS

FIGURE 36 PFIZER, INC.: SEGMENTAL REVENUE

FIGURE 37 PFIZER, INC.: GEOGRAPHICAL REVENUE

FIGURE 38 PROCTER & GAMBLE PHARMACEUTICALS: KEY FINANCIALS

FIGURE 39 PROCTER & GAMBLE PHARMACEUTICALS: SEGMENTAL REVENUE

FIGURE 40 PROCTER & GAMBLE PHARMACEUTICALS: GEOGRAPHICAL REVENUE

FIGURE 41 EMD SERONO, INC.: KEY FINANCIALS

FIGURE 42 EMD SERONO, INC.: SEGMENTAL REVENUE

FIGURE 43 EMD SERONO, INC.: GEOGRAPHICAL REVENUE



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.